创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: In Vitro Assay Platform Introduction

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-09 15:12
  • Views:

(Summary description)The In Vitro Assay Platform developed by InnoModels Biotechnology is an efficient and accurate assay. The platform is unique in that it uses cell-based technology for detection, enabling rapid and accurate identification of microorganisms such as bacteria, viruses and fungi.

InnoModels Biotechnology: In Vitro Assay Platform Introduction

(Summary description)The In Vitro Assay Platform developed by InnoModels Biotechnology is an efficient and accurate assay. The platform is unique in that it uses cell-based technology for detection, enabling rapid and accurate identification of microorganisms such as bacteria, viruses and fungi.

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-09 15:12
  • Views:
Information

The In Vitro Assay Platform developed by InnoModels Biotechnology is an efficient and accurate assay. The platform is unique in that it uses cell-based technology for detection, enabling rapid and accurate identification of microorganisms such as bacteria, viruses and fungi.
The platform's detection process is very simple: the sample to be detected is added to a specific petri dish and incubated on the detection platform. Afterwards, a special fluorescent dye is used to detect the presence of microorganisms in the sample. This is a very fast test and usually takes only a few hours to produce results.

 


The assay platform from InnoModels Biotechnology offers a number of advantages. The platform is very sensitive and is able to detect the presence of microorganisms, even in trace amounts, without missing them. The cellular technology used in the platform is more accurate than traditional testing methods and there are no false positives or misclassifications. The platform is very easy to operate and requires no special skills or equipment.
In addition, the platform has a wide range of applications. It can be used not only for disease treatment and monitoring in the medical field, but also for environmental protection, food safety and other fields. Therefore, the platform has been widely used and recognized in many fields.
The in vitro testing platform of InnoModels Biotechnology has the advantages of being fast, accurate, sensitive and easy to operate, and has a wide range of application value. It is believed that in the future, the platform will be applied in more fields, bringing more convenience and safety guarantee for people's health and life.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司